Shots:

• The collaboration is for the onset of P-Ib/II trial for assessing Zenith’s ZEN-3694 and Pfizer’s talazoparib in patients with LA or MTNBC
• Pfizer & Zenith to fund the trial with supply of their respective products and will retain rights for their own products
• ZEN-3694 is an inhibitor of BETi (bromodomain and extra-terminal domain inhibitor) currently evaluated in P-II in combination with enzalutamide for metastatic castration resistant prostate cancer

Ref: Zenith Epigenetics | Image: Omniriga